Clinical Curative Effect of Montelukast on Cough Variation Asthma(CVA) in Children

Objective:To investigate the clinical curative effect of Montelukast taken orally on cough variation asthma(CVA) in children.Methods: All the 48 examples aged from 4~14 years old diagnosed CVA were divided into treatment group(n=25) and control group(n=23) randomly.The children in treatment group took Montelukast orally 1 time a day(5mg/time for 6~14 years old,4 mg/time for 4~6 years old) and inhaled Budesonide Aerosol qd(each time 1 spurt,content 200 μg),and those in control group inhaled Budesonide Aerosol bid(each time 1 spurt,content 200 μg) only.Both groups inhaled Budesonide Aerosol with spacers and were observed for 12 weeks.Symptoms,peak expiratory flow rates(PEF),percentage of PEF to predicted value(PEF%pred) and side effects were recorded before and after treatment 3rd day,1 week,2 week,4 week and 12 week.Result: Both of the groups could reduce symptoms such as cough,and treatment group had better effect than control group(P0.01) at 3rd day,1 week after treatment,but there was not different between the two groups from 2 weeks after treatment.PEF%pred increased in both the groups after treatment,but it increased more remarkable 1 week,2 week and 4 week after treatment in treatment group than in control group.Conclusion: Montelukast has more quickly and better effect on CVA in children than glucocorticoid and can reduce the dose used of the latter.